Coinfection with visceral leishmaniasis and HIV is an emergent problem in several countries
around the world, particularly in Africa, the Indian subcontinent, and the Mediterranean …

While visceral leishmaniasis (VL) generally occurs in immunocompetent subjects in
endemic areas, it has been increasingly recognised as an important opportunistic infection …

With increasing numbers of immunocompromised patients a rise in the incidence of visceral
leishmaniasis has to be expected. Presenting a case of visceral leishmaniasis in an HIV …

Visceral leishmaniasis (VL) is a well-recognized opportunistic infection in patients with HIV-1
infection. Several reports indicate a rising trend in VL/HIV co-infection. The majority of …

The authors describe a case of visceral leishmaniasis in an intravenous drug abuser, HIV
seropositive patient. Visceral leishmaniasis was the first opportunist infection and diagnosis …

Leishmaniasis is an infectious disease in form of visceral (VL), cutaneous (CL), and
mucocutaneous (MCL) leishmaniasis. Immunocompromised patients have increased risk of …

Background: Human visceral leishmaniasis (VL) is a life-threatening protozoan disease
caused by parasites belonging to the Leishmania donovani complex. Ethiopia has the …

Visceral leishmaniasis (VL) has increased as a complicating infection in subjects with
human immunodeficiency virus (HIV) in countries bordering the Mediterranean sea [1] …

Leishmaniasis is considered an emerging opportunistic disease in human
immunodeficiency virus (HIV)–infected patients who have considerably variable clinical …

Visceral leishmaniasis (VL) is a zoonosis endemic in Latin America, with 96% of the cases
diagnosed in Brazil. The infection has been diagnosed in endemic and non-endemic areas …